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Protocol
AbstrACt
Introduction Previous studies comparing satisfaction with 
electronic and elastomeric infusion pumps are limited, and 
improvements in size and usability of electronic pumps 
have since occurred. The Comparing Home Infusion 
Devices (CHID) study plans to assess patient and nurse 
satisfaction with an elastomeric and electronic pump for 
delivering intravenous antibiotic treatment in the home. 
Secondary objectives are to determine pump-related 
complications and actual antibiotic dose administered, 
evaluate temperature variation and compare pump 
operating costs.
Methods and analysis The CHID study will be a 
randomised, crossover trial. A trained research nurse will 
recruit patients with infectious disease aged ≥18 years and 
prescribed ≥8 days of continuous intravenous antibiotic 
therapy from the Royal Adelaide Hospital (RAH) (Adelaide, 
Australia). Patients will be randomised to receive treatment 
at home via an elastomeric (Baxter Infusor) or an electronic 
(ambIT Continuous) infusion pump for 4–7 days, followed 
by the other for a further 4–7 days. Patient satisfaction will 
be assessed by a 10-item survey to be completed at the 
end of each arm. Nurse satisfaction will be assessed by 
a single 24-item survey. Patient logbooks and case notes 
from clinic visits will be screened to identify complications. 
Pumps/infusion bags will be weighed to estimate the 
volume of solution delivered. Temperature sensors will 
record skin and ambient temperatures during storage and 
use of the pumps throughout the infusion period. Costs 
relating to pumps, consumables, antibiotics and servicing 
will be determined. Descriptive statistics will summarise 
study data.
Ethics and dissemination This study has been approved 
by the RAH Human Research Ethics Committee (HREC/16/
RAH/133 R20160420, version 6.0, 5 September 2016). 
Study results will be disseminated through peer-reviewed 
publications and conference presentations. The CHID 
study will provide key insights into patient and provider 
satisfaction with elastomeric and electronic infusion 
pumps and inform future device selection.
trial registration number ACTRN12617000251325; Pre-
results.
bACkground
Ambulatory intravenous infusion of anal-
gesics, chemotherapy and antimicrobials 
enables suitable patients to be treated in the 
home care setting, as an alternative to inpa-
tient hospital care.1 2 This reduces demand 
on hospital beds, provides cost savings and 
strengths and limitations of this study
 ► Crossover randomised trial design to determine 
patient and nurse satisfaction with elastomeric and 
electronic infusion pumps for continuous infusions 
in the home setting.
 ► Measurement of ambient and skin temperature 
throughout the infusion period.
 ► Recording and analysis of pump, vascular access 
device and antibiotic complications, plus estimation 
of dose delivered.
 ► Home nursing staff have more experience using 
elastomeric infusion devices in comparison to 
electronic infusion devices.
 ► Unable to detect early emptying of elastomeric 
devices.
 ► Internal infusion solution temperature cannot be 
ascertained.
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improves patient well-being.3–6 The administration of 
antibiotics in the outpatient setting is well established 
worldwide,6 and in a 7-year Australian-based study anti-
biotics were administered to more than 70% of patients.7 
A range of ambulatory infusion pumps are available for 
use in the home setting, including mechanically powered 
disposable pumps and electronic reuseable pumps. Each 
device type has key differences in functionality and oper-
ation.
Disposable elastomeric pumps are widely used for 
home infusions, both in Australia5 and internationally.1 
Elastomeric pumps contain a fluid reservoir made of a 
flexible elastomer that is stretched when filled, creating 
a high driving pressure. The flow rate is set by narrow 
bore tubing, known as a flow restrictor, in the line.1 
Advantages of elastomeric pumps include ease of oper-
ation, lightweight, silent operation, disposability and 
independence from an external power supply.2 8–12 The 
limitations of elastomeric pumps include a predeter-
mined flow rate,1 8 13 14 variability of infusion duration,10 15 
diluent restrictions,13 absence of warnings or alarms if 
the infusion occludes,10 14 16 and limited peer-reviewed 
data on antibiotics compatible with the elastomeric reser-
voir material at temperatures observed in the home.17 18 
These pumps typically have a stated accuracy in the range 
of ±15% under a specific set of conditions, but flow rate 
can be affected by a range of factors including variation 
in temperature, pump height, viscosity, filling volume and 
storage conditions.1 9 19 Difference between clinical and 
calibrated conditions may result in flow rate variations of 
up to ±50%.5 15
Portable electronic pumps use a battery source to 
power a fluid pumping mechanism connected to a reser-
voir of infusion solution. Electronic pumps offer more 
accurate flow rates, with a stated accuracy in the order of 
5%–8%.12 20 Built-in alarms alert users to any changes in 
flow and/or occlusion, enabling healthcare providers to 
identify and respond to problems in a timelier manner.14 
Other advantages include programmable options,20 21 the 
ability to vary infusion rates without interrupting the infu-
sion or disconnecting the closed intravenous system,22 and 
more reservoir options.20 Potential disadvantages with the 
use of electronic infusion pumps include programming 
and user interface errors,21 pump noise13 and greater 
capital purchase cost of the pump.1
Pump selection may have implications for satisfaction 
with care and clinical outcomes among patients treated 
in the home. Reductions in flow rate with an elastomeric 
pump due to variation in temperature, for example, 
might contribute to a poor clinical response or extended 
treatment duration. Higher than expected flow rates have 
the potential for toxic medication levels, especially for 
those with a narrow therapeutic window.23 Poor patient 
satisfaction with a larger pump may lead to reduced 
patient adherence2 or a reduction in mobility.24 Although 
both elastomeric and electronic infusion pumps are 
used in the home setting, few studies have compared 
user preferences. One small crossover trial comparing 
the elastomeric Baxter Infusor to the electronic CADD-1 
for continuous infusion of fluorouracil among 10 outpa-
tients reported that all patients preferred the elastomeric 
pump.23 The time spent by nurses with each pump was 
assessed, but the nurses were not questioned about their 
satisfaction or pump preference. A comparative study 
assessing satisfaction with the elastomeric Baxter LV5 
Infusor and two electronic alternatives (Graseby 9300 
Ambulatory Infusion Pump and Microjet Infusion Pump) 
among 68 patients showed very good satisfaction with the 
Baxter and Graseby pumps; however, pump crossover was 
not incorporated into the study design.22
Elastomeric pumps are often stored in a refrigerator 
prior to use18 and following connection to a patient, elas-
tomeric pumps and infusion reservoirs are exposed to 
the home environment for the duration of the infusion. 
However, there is limited recent data available regarding 
temperature variation in the home setting where infu-
sions take place.18 Changes in temperature can impact 
on drug stability,18 25 infusion solution viscosity and 
elastomeric infusion duration18 26 due to its impact on 
elastomeric material properties. Also, during use, the 
restrictor element of an elastomeric pump is taped to 
the patient’s skin, relying on that skin temperature to 
regulate flow rate and further data on skin temperature 
variation during infusion is required.
Similarly, few studies have compared the operating 
costs associated with elastomeric and electronic pumps 
and recent data is lacking. A narrative review of studies 
published between 1989 and 2001 showed no clear cost 
advantage of one type of pump over another.1 However, 
there was considerable variation in the methods used to 
compare costs, and an up-to-date comparison is required.
The Comparing Home Infusion Devices (CHID) study 
will compare and contrast an elastomeric infusion pump 
with an electronic infusion pump for delivery of contin-
uous intravenous antibiotics in the home setting. The 
primary aim of this study is to evaluate both patient and 
nurse satisfaction with each type of pump. Secondary 
aims are: (A) determine complications relating to the 
infusion pump, vascular access device (VAD) and antibi-
otic therapy during home infusions; (B) estimate average 
flow rate and dose of the antibiotic administered with 
each pump; (C) examine variation in ambient tempera-
ture during storage, and variation in skin and ambient 
temperatures during continuous home infusion; and (D) 
compare the operating costs associated with each type of 
pump.
MEthods
Study design and setting
The CHID study is a single-centre, prospective, 
randomised, crossover trial with 1:1 allocation of patients 
to receive either a portable electronic pump for 4–7 days, 
followed by an elastomeric pump for 4–7 days, or vice 
versa, to deliver a continuous intravenous antibiotic infu-
sion in the home setting (figure 1). The crossover trial 
group.bmj.com on November 9, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
 3Hobbs JG, et al. BMJ Open 2017;7:e016763. doi:10.1136/bmjopen-2017-016763
Open Access
design was chosen to enable direct comparison between 
both pump types by patients and home nursing staff. Due 
to the nature of the study and the visibility of the infusion 
pumps, this will be an open-label study.
Patients will be recruited from the inpatient wards of 
the Royal Adelaide Hospital (RAH), a 640-bed public 
teaching hospital in Adelaide, South Australia. An 
external home nursing service provider, Royal District 
Nursing Service (RDNS) South Australia, will provide 
home care to participants as per current practice for 
metropolitan-based patients. In Australia, antibiotics 
administered via intravenous infusions in the home 
setting are generally administered as a continuous infu-
sion over a 24-hour period, with nursing staff vising once 
per day. During the home visit, the nurse will disconnect 
the previous pump, assess the line and dressings, attach 
the new infusion pump and attend to any other clinical 
needs of the patient. No patients will undertake self-ad-
ministration while enrolled in the CHID study.
This trial has been registered with the Australian New 
Zealand Clinical Trails Registry at http://www. anzctr. org. 
au/ (ACTRN12617000251325) (table 1).
Participants
Patients
Patients aged 18 years or older with approval from the 
RAH Infectious Diseases (ID) unit to receive intravenous 
antibiotic therapy in the home via a continuous 24-hour 
infusion for a minimum of 8 days will be eligible for 
inclusion. Patients who are unable to provide informed 
consent, those who are unable or unwilling to complete 
the study logbook and survey in English, pregnant women 
and patients who are immobile or require 24 hours 
nursing care will be excluded. Patients with a skin allergy 
or contact dermatitis to stainless steel will also be excluded 
from the study.
Home nursing staff
Nurses who have provided home care for one or more 
study participants will be eligible to complete a survey.
study procedures
Patient recruitment
A trained research nurse will liaise with the RAH ID unit 
during weekdays and obtain a list of hospital inpatients 
approved to receive continuous intravenous antibiotic 
treatment in the home setting. The research nurse will 
assess each patient to determine if the patient meets the 
study entry criteria and provide eligible patients with 
verbal and written information about the trial. Written 
informed consent will be obtained prior to leaving 
hospital.
Randomisation
After obtaining written consent, patients will be 
randomised to receive either the elastomeric or electronic 
infusion pump to deliver the first week of intravenous 
antibiotic therapy, followed by the alternative pump for 
the subsequent week. Randomisation will be undertaken 
by the RAH Pharmacy Department when the discharge 
prescription is received. Patients will be randomly allo-
cated to either crossover arm by a computer-generated 
sequencing program.
Infusion devices
The two specific brands of infusion pumps to be 
compared in the CHID study are the Baxter Infusor 
(Baxter Healthcare Corporation, Illinois, USA) and the 
ambIT Continuous (Summit Medical Products, Utah, 
USA) (figure 2).
The Baxter Infusor is a single-use, elastomeric, portable 
infusion pump and consists of an elastomeric membrane 
within a ridged outer shell. The integrated administra-
tion line is primed at the time of dispensing or at the 
patient bedside and is attached via a luer lock connector 
to the patient’s VAD. Varying sizes and flow rates are avail-
able; however, the CHID study will only use the devices 
marketed to provide a 24-hour continuous infusion. A 
commonly used version has dimensions of approximately 
170 mm in length by 68 mm in diameter, and weighs 65 g 
when empty. Elastomeric pumps have a silent operation 
with no alarms. Confirmation of fluid delivery is approxi-
mated by examining the size of the fluid reservoir within 
the clear, hard casing.
The ambIT Continuous infusion pump is an electronic 
reuseable portable device. The dimensions of the pump 
are 55×36×175 mm and it weighs 181 g (including two 
AA batteries). Flow rates can be programmed between 
0.1 and 125 mL/hour and will be set to deliver a 24-hour 
continuous infusion. The pump mechanism is a micro-
processor-controlled rotary peristaltic with some audible 
pump noise. Visual and audible alarms occur for the 
Figure 1 Flow diagram of crossover study design.
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Table 1 Trial registration data
Data category Information
Primary registry and trial 
identifying number
Australian New Zealand Clinical Trials Registry (https://www.anzctr.org.au)
Ref No. ACTRN12617000251325
Date of registration 17 February 2017
Public title Comparing Home Infusion Devices for antibiotic treatment—CHID Study
Scientific title A randomised crossover trial evaluating patient and nurse satisfaction of the electronic 
portable infusion device (ambIT Continuous) versus elastomeric delivery (Baxter Infusor) for 
the continuous administration of antibiotics in the home in patients with infectious disease
Trial acronym CHID
Health conditions Any infectious disease requiring intravenous antibiotic therapy and suitable for treatment 
via a continuous infusion in the home setting
Study type Interventional
Intervention code Treatment: devices
Control treatment Treatment administered via an elastomeric infusion pump
Key inclusion criteria Suitable for ambulatory home antibiotic therapy as approved by infectious diseases 
specialist
Inpatient of Royal Adelaide Hospital
Can provide informed consent
Require 8 days minimum therapy
Able to provide feedback through questionnaire and logbook
18 years of age or older
Key exclusion criteria Patient is unable or unwilling to fill out the patient questionnaire survey and or logbook
Skin allergy or contact dermatitis to stainless steel
Patient’s primary clinician is unwilling to enrol patient
Pregnancy
Patient is totally dependent on care for all daily needs and/or is immobile
The following antibiotics are excluded due to restricted shelf life: ceftazidime, ticarcillin/
clavulanate
Recruitment state South Australia
Recruitment hospital The Royal Adelaide Hospital—Adelaide
Funding source 1 Government of South Australia, Department of Further Education, Employment, Science 
and Technology (now Department of State Development)
Funding source 2 CPIE Pharmacy Services, Findon, South Australia
Primary sponsor Flinders University, Bedford Park, South Australia
Other collaborator CPIE Pharmacy Services, Findon, South Australia
Ethics committee Royal Adelaide Hospital Human Research Ethics Committee, Approval No. R20160420
Figure 2 Infusion pumps used in the Comparing Home Infusion Devices study. (A) Baxter Infusor. (B) ambIT Continuous.
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following conditions: occlusion downstream, cassette not 
mounted, low battery, dead battery, malfunction and infu-
sion complete. The ambIT Continuous is connected to a 
filled infusion container prior to infusion.
Supply of the infusion device and antibiotic
Prefilled elastomeric pumps will be sourced from the 
manufacturer and dispensed by the RAH Pharmacy 
Department, as per standard practice at the RAH. CPIE 
Pharmacy Services (Adelaide, Australia) will prefill the 
infusion containers, attach and program the electronic 
pump at a fixed flow rate and dispense for the individual 
patient. (CPIE Pharmacy Services are providing the loan 
of the electronic pumps and the labour involved with the 
preparation of electronic infusions as in-kind support 
for the trial.) Pumps will be supplied to the patient at 
the time of leaving hospital (day 1) and at clinic visit 1 
(table 2). Antibiotics prescribed will be those which have 
sufficient stability for a 24-hour continuous infusion and 
are commonly used in the home setting in Australia. 
These may include: flucloxacillin, ceftriaxone, cephalo-
thin, cephazolin, clindamycin and vancomycin.
Patient education and monitoring
All patients will receive education regarding their VAD and 
antibiotic therapy as per normal hospital practice. Partici-
pants will receive written information sheets produced by 
the pump manufacturers and verbal education from the 
study nurse relating to each pump type prior to leaving 
hospital. Patients will also be given information about the 
temperature sensor that will be placed on the skin, and 
how to care for it.
The first infusion pump will be connected to the patient 
on the day of leaving hospital (day 1; refer to table 2). 
From day 2 onwards, patients will be reviewed daily in 
their home by an RDNS nurse. Patients will also attend a 
clinic appointment with a RAH ID doctor at least weekly 
for routine clinical monitoring, pump and VAD checks, 
and any blood tests deemed necessary by the ID doctor. 
The ID doctor will review any adverse events experienced 
during the study period and document in the hospital 
case notes as per standard practice. The ID doctor will 
assess treatment response during the clinic visits and may 
amend the duration of antibiotic therapy if required. This 
is standard care for patients receiving home treatment 
with antibiotic therapy who are under the care of the ID 
unit at the RAH.
Nurse training and clinician support
Elastomeric infusion pumps are the most common type of 
infusion pump used for delivering continuous antibiotic 
infusions in the home setting in South Australia; however, 
home care nurses may have no previous experience using 
the ambIT Continuous electronic infusion pump. To 
ensure competency, all RDNS nurses providing a home 
visit for patient(s) enrolled in the trial will receive training 
on the ambIT Continuous pump via a short, custom-
made, online video that will be disseminated through the 
RDNS training platform. The video was developed with 
input from the clinical educators employed by the device 
distributor, CPIE Pharmacy Services and the RDNS. All 
steps that were deemed essential for the use of the ambIT 
Continuous electronic infusion pump in the CHID study 
were covered in the video. The content was validated 
and refined based on input from the CHID study inves-
tigators, pharmacists, nursing staff and laypersons. The 
final version of the video was approved by the nursing 
provider. The home nurses will also receive an informa-
tion sheet about the CHID study, the temperature sensor 
and the elastomeric pump used in the trial. This training 
material will be provided prior to enrolment of the first 
participant.
Home nurses will also be provided with a communi-
cation pathway to access technical assistance during the 
trial period. Home nurses and other health professionals 
providing care for patients enrolled in the study will be 
encouraged to contact the 24-hour telephone technical 
Table 2 Patient timeline
In 
hospital














First infusion device connected x
Temperature sensor applied to patient’s forearm x
Home nursing staff visit patient x x x
Patient completes logbook x x x x x
Clinical progress assessment x x
Patient completes satisfaction survey x x
Patient crossover to other infusion device x
Discharge from trial and patient handover x
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support service should a pump-related issue occur during 
the study period (eg, alarm with the ambIT Continuous).
Logbooks
All patients will be asked to complete a logbook daily, to 
record details of any concerns or complications related 
to the infusion pump, any alarms that occurred and any 
phone calls that were required during the study period. 
In addition, patients will be asked to record the time 
each pump is connected and disconnected. Nurses will 
be asked to review the logbook each day and all logbooks 
will be reviewed weekly by the research nurse during the 
clinic visit.
Patient and nurse satisfaction surveys
Each patient will be asked to complete a survey at their 
clinic visits (table 2) to assess their experience and satis-
faction with the type of pump most recently used. The 
patient surveys (see online supplementary materials 1 
and 2) for each device include 10 questions addressing 
pump characteristics (weight, size, noise), the ability to 
perform daily activities, ease of use of the pump and 
usefulness of the information sheet, answered with a 
Likert scale. There is also a free-text section to report prob-
lems with the pump, and room for general comments. 
The survey to be completed following treatment with the 
electronic device includes an additional question on the 
pump alarms.
All home care nurses who provide care for any patient 
enrolled in this study will be invited to complete a 24-item 
nurse satisfaction survey (see online supplementary 
material 3). Nurses will be asked to respond to questions 
regarding their experience and satisfaction with each 
pump type using the Likert scale provided.
The patient and nurse survey questions were initially 
developed by two clinician members of the research 
team using the existing literature2 21 23 as a guide. The 
questions were revised following input from other 
members of the research team and a statistician. The 
face and content validity of the revised survey questions 
were then assessed by 10 people, including pharmacists, 
nurses, researchers and laypersons, who were asked to 
provide feedback on clarity and whether all desired 
information would be captured using the surveys. 
Following this, minor revisions were made to improve 
readability of the surveys.
Weight of elastomeric device and infusion containers
To estimate the delivery accuracy of the infusion pumps, 
all elastomeric pumps and infusion containers attached 
to the electronic pumps will be weighed pre and post-
administration. The difference in weight will be used to 
calculate the total volume infused, based on the density of 
the drug and diluent in the infusion container or pump. 
The volume infused will be determined by dividing mass 
by density. This, along with the start and stop times of 
each pump recorded in the patient logbooks, will allow 
calculation of an average flow rate throughout the infu-
sion period.
Temperature sensors
Patient skin temperature will be continuously monitored 
throughout the trial period using an iButton DS1921H 
(Maxim Integrated, CA, USA) digital temperature sensor. 
The iButton has previously been validated for accuracy, 
response time27 and skin reaction.28 With an accuracy 
of ±1°C and a temperature range of +15°C to +46°C, 
the iButton will record patient skin temperature every 
10 min. The temperature sensor will be applied by the 
research nurse to the patient’s forearm on the day of 
leaving hospital and kept in place using the same adhe-
sive dressing that is used to attach the VAD to the skin. 
The sensor will be replaced during the ID clinic visit 
1 (table 2) and removed during the ID clinic visit 2.
Ambient temperature surrounding the infusion 
pump will be monitored continuously using the iButton 
DS1921G (Maxim Integrated) digital temperature sensor. 
This sensor has a temperature range of −30°C to +70°C. 
The temperature sensor will be attached to the outside of 
the elastomeric pumps and to the outside of the infusion 
containers connected to the electronic pumps at the time 
of dispensing. Temperature will be monitored at 10 min 
intervals.
Data will be downloaded at the end of each week from 
all sensors using Thermodata Viewer software (Thermo-
data, Victoria, Australia).
Patient handover
At the end of the trial period, patients will revert back 
to the standard clinical care under the RAH, and be 
discharged or continue antibiotic therapy as required.
data collection and monitoring
Demographic and clinical information will be extracted 
from the hospital medical records for each participant at 
baseline and after each ID clinic visit using a standardised 
data collection form. Data from the temperature sensors, 
along with the pre and postweight data of the pumps and 
infusion containers, will be collated by the research nurse 
for analysis.
A protocol steering committee comprising study inves-
tigators and an independent ID physician will regularly 
review study progress and monitor recruitment, protocol 
adherence, antibiotic type and safety-related matters. 
An internal study monitor will inspect the case record 
files during the study period. Any serious adverse events 
occurring during the study will be immediately reported 




The primary outcome is to evaluate patient and nurse 
satisfaction with an elastomeric and electronic infusion 
pumps for delivery of intravenous antibiotics in the home 
setting. This will be determined using responses to the 
patient and nurse satisfaction surveys described above. 
Subquestions will be averaged and means compared 
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between the two pumps. In the patient survey, partici-
pants are asked to rank their satisfaction for the ‘ability 
to carry out the following activities’ with each pump type. 
The activities addressed are the ability to shower or bathe, 
sleep, sleep due to noise level and perform other daily 
activities. There is also a question on the overall experi-
ence with the pump, including attributes such as ease of 
use, easy to carry, reliability, feeling of safety and overall 
performance. A question addressing attributes that may 
affect patient satisfaction asks about the size, shape, 
weight and noise of the pump.
The nurse survey asks participants to rank their satis-
faction with both devices with reference to safety of the 
pump, ease of use of the pump and overall satisfaction. 
They are also asked to consider various characteristics of 
each pump including: acceptable size for healthcare staff, 
ease of attaching/detaching to the patient, ease of deter-
mining fluid flow and reservoir emptying.
secondary outcomes
Complications
Data collected from the two patient surveys, logbooks 
and hospital case notes will be assessed to identify the 
prevalence of complications relating to each of the 
infusion pumps or the VAD, including leaks, occlusions 
and incomplete infusions, as well as medication-related 
complications, unplanned phone calls or extra home 
visits that were required.
Dose delivered
The dose of antibiotic received by the patient over a 
24-hour period will be estimated based on the volume of 
infusion solution delivered by the infusion pump. The 
estimated dose received will be compared with the total 
daily dose prescribed by the ID physician. The average 
flow rate each day will be approximated based on the 
volume of infusion solution delivered and the connection 
and disconnection times recorded in the patient logbook.
Temperature
The average and peak ambient temperatures surrounding 
the infusion pump will be determined during (1) storage 
prior to patient connection and (2) while connected to 
the patient. Temperature data recorded from the patient’s 
skin will be compared with calibration conditions for 
peripheral skin temperature used by manufacturers of 
elastomeric pumps.
Device costs
Data on purchase cost of pumps, disposables (including 
batteries) and antibiotics will be obtained from the RAH 
Pharmacy Department and CPIE Pharmacy Services. 
Service and cleaning cost of the reuseable electronic 
pump will be recorded by CPIE Pharmacy Services. The 
estimated volume remaining in returned pumps and 
infusion containers, together with consideration of the 
connection and disconnection times, will be used to 
estimate the cost of any remaining (underinfused) medi-
cation. Additional medication costs relating to wastage 
due to dose not administered or due to prescription 
changes made during the study period will also be deter-
mined.
AnAlysIs
Given the limited number of studies comparing patient 
satisfaction with infusion pumps to guide a sample size 
calculation, and on the advice of a consultant statistician, 
a post hoc power analysis will be performed after enrol-
ment of the first 10 patients to estimate the minimum 
number of patients required for the trial. Descriptive 
statistics will be used to summarise patient character-
istics, responses to surveys and temperature variation. 
Patient and nurse satisfaction between devices will be 
assessed individually using the Wilcoxon signed-ranks 
test of survey data and any variation in exposure time 
between devices accounted for as necessary. The influ-
ence of nurse prior experience on satisfaction will be 
assessed using the Kruskal-Wallis test. Complication types 
and frequency will be compared using χ2 test or Fisher’s 
exact test. Dose delivered will be compared using a paired 
t-test for normally distributed data or Wilcoxon signed-
rank test for non-normally distributed data. Analysis of 
variance will be used to determine effects of temperature 
on average flow rate. All survey data for patients who have 
completed a minimum of 4 days with each device will be 
included. Patients who do not complete a questionnaire 
will be excluded from the patient satisfaction analyses, 
but data will still be included in the temperature analysis. 
Quantitative data will be analysed using Stata Statistical 
Software (StataCorp, College Station, TX).
Thematic analysis will be used to analyse any responses 
in the free-text boxes of the surveys. Two members of the 
research team will carefully read all free-text responses 
to establish familiarisation and identify common themes. 
The researchers will categorise the free-text responses 
according to these themes and discuss to reconcile any 
disagreement. Specific quotes from the free-text sections 
of the survey may be used to illustrate results from the 
thematic analysis.
EthICs And dIssEMInAtIon
The CHID study has been approved by the RAH Human 
Research Ethics Committee (Reference No. HREC/16/
RAH/133 R20160420). Any protocol changes will be 
communicated to ethics, trial registry and investigators as 
required.
Data collected as part of this study will be treated 
confidentially and stored securely at the RAH ID Unit 
in accordance with hospital guidelines for clinical trial 
research. Paper-based study documents will be securely 
locked and will be accessed only by the research team. 
Electronic data will be stored in a password-protected 
database. Data will be stored in a reidentifiable manner 
(using a unique patient identifier) should a patient with-
draw consent. Final data set access will be limited to study 
investigators.
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Study results will be disseminated through peer-re-
viewed publications and conference presentations. 
Clinicians participating in this research will have access 
to a copy of a final report summarising key study find-
ings. Research participants will be able to request a lay 
summary of findings.
dIsCussIon
The CHID study is the first study to assess patient and nurse 
satisfaction with the Baxter Infusor elastomeric pump and 
the ambIT Continuous electronic pump for delivery of 
continuous intravenous home antibiotic therapy. Compar-
ison of patient satisfaction between a hospital in the home 
service and inpatient treatment shows that patients gener-
ally are more satisfied with home treatment29 30 as they 
preferred their home environment and could resume daily 
activities. Research into the human factors that influence 
the success of home healthcare includes personal, envi-
ronmental and technology aspects, as well as the tasks that 
need to be undertaken.31 Physical and technical attributes 
of the device such as its size, portability and instructions 
must be considered along with the capabilities of the user 
and their familiarity with the tasks, to gain user acceptance 
and user competence.31 32 However, there are few studies 
that compare satisfaction between two infusion pumps, 
and ask questions about the device attributes that influence 
patient and/or nurse satisfaction. We identified one cross-
over study in which all patients preferred the elastomeric 
over the electronic pump, with the main reasons attributed 
to increased size and weight of the electronic pump.23 
However, the CADD-1 electronic pump assessed in this 
study weighed 425 g, whereas the ambIT Continuous is one 
of the lighter electronic infusion pumps available at 181 g.33 
Developments in electronic pump design (including weight 
reduction) since these studies were published indicate the 
need to revisit patient and staff preferences. This study will 
provide key insights into patient and provider satisfaction 
with elastomeric and electronic infusion pumps which is 
particularly important given that few studies have done this 
directly. User’s perspectives on technology that is used in 
the home should inform future device design to improve 
user-friendliness.32
The main advantage of electronic pumps is a more 
accurate flow rate but elastomeric pumps are perceived 
to be cheaper and easier to use.1 Elastomeric pump accu-
racy also degrades with multiple environmental factors 
and this has raised clinical concerns. In a previous study 
where elastomeric pumps were weighed several times a 
day during an inpatient infusion, the estimated flow rate 
exceeded the manufacturer’s stated accuracy of ±15% in 
47% of infusions for the elastomeric EasyPump and 35% 
of infusions for the elastomeric Infusor LV5.16 The CHID 
study will weigh all infusion pumps and containers before 
and after use, and connection times will be recorded in 
logbooks. This will enable us to estimate the dose of anti-
biotic delivered and average flow rate for each type of 
infusion pump.
The CHID study will also provide comprehensive 
information on the home environment in which these 
pumps are used. It will build on a previous study assessing 
ambient autumn temperature data collected from six 
healthy volunteers in the home (conducted in Adelaide, 
South Australia), where infusion solution temperatures 
could exceed 30°C.18 This is important for understanding 
how temperature influences flow rate and pump accu-
racy, as well as providing valuable data for future drug 
stability studies.
Another strength of the CHID study is the ability to 
record skin temperature variation during continuous 
home infusions. Variations in temperature of the restric-
tive element taped to the skin will alter the flow rate 
of an elastomeric pump.34 Sarabia et al reported wrist 
temperature in healthy subjects can vary by up to 6°C over 
24 hours under normal living conditions.35 This natural 
variation alone would exceed the stated ±15% accuracy 
of the elastomeric pump used in this study. Recorded 
skin temperature data will inform future bench testing of 
these pumps.
There are several limitations with our study design. The 
elastomeric pump used for the CHID study is the current 
standard of care for this patient cohort, so the home 
nurses are likely to have greater familiarity with its use. 
Home nurses will be educated about the use of the elec-
tronic pump and have access to technical assistance, but 
nurse satisfaction may be biased due to differences in prior 
experience and the recent timing of training. The home 
nurses will have access to written educational materials 
and an online video regarding the use of the electronic 
pump; however, one of the limitations in the study design is 
that we could not provide hands-on training for all nurses 
employed by the home nursing organisation. Furthermore, 
although patients and staff will be educated regarding the 
use of the logbook, and adherence checked at each clinic 
visit, it is possible that recording may diminish over time, 
leading to an underestimation of complications and unex-
pected call-outs. Incomplete recording of connection and 
disconnection times may also impact on complete capture 
of data for analyses relating to average flow rates and cost. 
A further limitation is that the CHID study will not be able 
to detect rapid infusions (early emptying), as the elasto-
meric pump or infusion container will only be weighed 
before and after the infusion takes place. Finally, data will 
be limited to the external temperature of the elastomeric 
pump or infusion container and not the internal tempera-
ture of the solution.
In conclusion, the CHID study will provide important 
information regarding patient and nurse satisfaction with 
elastomeric and electronic infusion pumps, and will eluci-
date differences in patient safety and treatment costs to 
inform future device selection. Skin and ambient tempera-
ture data collected for the CHID study will provide a basis 
for expanded drug stability studies and flow rate bench 
testing of elastomeric infusion pumps.
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trIAl stAtus
Planned patient recruitment from February 2017 to 
October 2017.
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